Astellas

News

Astellas brings its first digital health product to US

Astellas is ready to launch its first digital health offering in the US, a toolkit dedicated to providing at-home monitoring for people living with heart failure.

News

Bayer files first application of menopause drug elinzanetant

Bayer has filed for approval in the US for elinzanetant as a non-hormonal treatment for menopausal symptoms such as hot flushes, with a rival therapy from Astellas in its sights.

Oncology

ASCO 2024 - Michael Petroutsas

Just two months into his new position as US president and head of commercial for Astellas, Michael Petroutsas joined pharmaphorum editor-in-chief Jonah Comstock for a conversation on the si

News

Astellas refiles CLDN 18.2 cancer drug after FDA knockback

The US FDA has started a fresh review of Astellas' zolbetuximab, trying to become the first claudin (CLDN) 18.2-targeting drug to reach the US market, after turning it dow

News

Astellas expands Poseida alliance on solid tumour CAR-Ts

Astellas has clearly been impressed with a partnership signed last August with Poseida Therapeutics on the development of cell therapies for solid tumours, as it has just

News

Astellas’ generic Myrbetriq defence knocked back again

Low-cost competition in the US to Astellas’ Myrbetriq for urinary incontinence has arrived after a court recommended denying an injunction on the launch of generics.

Astellas brings its first digital health product to US

Bayer files first application of menopause drug elinzanetant

ASCO 2024 - Michael Petroutsas

Astellas refiles CLDN 18.2 cancer drug after FDA knockback

Astellas expands Poseida alliance on solid tumour CAR-Ts

Astellas’ generic Myrbetriq defence knocked back again

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

Astellas

Editor's Picks